Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 7/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934522 | 0.86 | PDE10A (0.48) | RAB9ANPC1PIK3CGKDM4EMAPT | |
| SCHEMBL1019063 | 0.82 | KDM4E (0.47) | RAB9ANPC1PIK3CGKDM4ETP53 | |
| SCHEMBL13317045 | 0.82 | KDM4E (0.40) | RAB9ANPC1PIK3CGKDM4EMAPT | |
| SCHEMBL5270607 | 0.78 | PIK3CG (0.68) | RAB9ANPC1PIK3CGKDM4EMAPT | |
| SCHEMBL31417130 | 0.78 | KDM4E (0.53) | RAB9ANPC1KDM4EMAPTTP53 | |
| SCHEMBL31417248 | 0.78 | AURKA (0.42) | RAB9ANPC1PIK3CGKDM4EMAPT | |
| SCHEMBL25465501 | 0.77 | CYP1A2 (0.45) | RAB9ANPC1PIK3CGKDM4EMAPT | |
| SCHEMBL5056012 | 0.77 | RAB9A (0.44) | RAB9ANPC1PIK3CGKDM4EMAPT | |
| SCHEMBL7063800 | 0.77 | RAB9A (0.71) | RAB9ANPC1KDM4EMAPTTP53 | |
| SCHEMBL3299677 | 0.76 | TP53 (0.53) | RAB9ANPC1KDM4EMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319696-B2 | 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections | CUROVIR AB (SE) | 2025-06-03 | — | — | US | disclosed |
| CN-112969703-B | Compounds for the treatment of viral infections | 库洛维公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3864017-B1 | 2,6-DIMETHYL-N-((PYRIDIN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDIN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS | CUROVIR AB (SE) | 2023-07-26 | — | — | EP | disclosed |
| EP-4028131-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210340147-A1 | 2,6-DIMETHYL-N-((PYRIDlN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDlN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDlN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS | CUROVIR AB (SE) | 2021-11-04 | — | — | US | disclosed |
| CN-108290843-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-3864017-A1 | 2,6-DIMETHYL-N-((PYRIDIN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDIN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS | CUROVIR AB (SE) | 2021-08-18 | — | — | EP | disclosed |
| CN-112969703-A | 2, 6-dimethyl-N- ((pyridin-4-yl) methyl) imidazo [1,2-b ] pyridazin-8-amine and 2, 5-dimethyl-N- [ (pyridin-4-yl) methyl ] pyrazolo [1,5-a ] pyrimidin-7-amine derivatives for the treatment of viral infections | 库洛维公司 | 2021-06-15 | — | — | CN | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| WO-2008036541-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036541-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| EP-1218381-B1 | AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES | NEUROGEN CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| US-6476038-B1 | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION | 2002-11-05 | — | — | US | disclosed |
| EP-1218381-A2 | AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001023388-A2 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | RAB9A 1262/4885NPC1 830/4885PIK3CG 3985/4885 |
| US-12319696-B2 | 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections | ZC3HAV1, IFNAR1, ZYX | RAB9A 2142/4885NPC1 371/4885PIK3CG 2921/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | RAB9A 1377/4885NPC1 723/4885PIK3CG 3321/4885 |
| US-20210340147-A1 | 2,6-DIMETHYL-N-((PYRIDlN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDlN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDlN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS | NSUN2, EIF2AK2, METTL16 | RAB9A 2468/4885NPC1 1505/4885PIK3CG 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.